This Article Full Text Full Text (PDF) All Versions of this Article: 0008-5472.CAN-08-2001v1 69/3/1182    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Medarova, Z. Articles by Moore, A. Search for Related Content PubMed PubMed Citation Articles by Medarova, Z. Articles by Moore, A.

Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging

Molecular Imaging Laboratory, MGH/HST Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts

Requests for reprints: Anna Moore, MGH/MIT/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Room 2301, Building 149, 13th Street, Charlestown, MA 02129, Phone: 617-724-0540; Fax: 617-726-7422; E-mail: amoore{at}helix.mgh.harvard.edu.

Key Words: underglycosylated mucin-1 • chemotherapy • magnetic resonance imaging • optical imaging • targeted probe

With the emerging concept of individualized cancer therapy, it becomes crucial to develop methods for the noninvasive assessment of treatment outcome. With this in mind, we designed a novel approach for the comprehensive evaluation of response to chemotherapy with the established agent doxorubicin in a preclinical breast cancer model. This approach delivers information not only about change in tumor size but also about target antigen expression. Our strategy relies on a tumor-specific contrast agent (MN-EPPT) targeting the underglycosylated MUC-1 (uMUC-1) tumor antigen, found on more than 90% of breast cancers and predictive of chemotherapeutic response. MN-EPPT consists of superparamagnetic iron oxide nanoparticles (MN) for magnetic resonance imaging, modified with Cy5.5 dye (for near-IR fluorescence optical imaging), and conjugated to peptides (EPPT), specifically recognizing uMUC-1. In vivo, treatment of mice bearing orthotopic human breast carcinomas with doxorubicin led to a reduction in tumor mass and resulted in down-regulation of uMUC-1. The tumor-specific accumulation of MN-EPPT allowed the assessment of change in tumor volume by noninvasive imaging. Furthermore, in mice injected with MN-EPPT, tumor delta-T2 was significantly reduced after treatment with doxorubicin, indicating a lower accumulation of MN-EPPT and reflecting the reduced expression of uMUC-1. With these studies, we have shown the utility of magnetic resonance imaging for the multiparametric characterization of breast tumor response to chemotherapy. This approach has the potential of significantly advancing our ability to better direct the development of molecularly targeted individualized therapy protocols because it permits the monitoring of therapy on a molecular scale. [Cancer Res 2009;69(3):1182–9]

This article has been cited by other articles:

				S. Jiang, M. K. Gnanasammandhan, and Y. Zhang Optical imaging-guided cancer therapy with fluorescent nanoparticles J R Soc Interface, September 16, 2009; (2009) rsif.2009.0243v1. [Abstract] [Full Text] [PDF]